204 related articles for article (PubMed ID: 35535819)
81. C-terminal BRE inhibits cellular proliferation and increases sensitivity to chemotherapeutic drugs of MLL-AF9 acute myeloid leukemia cells.
Pun CC; Lee KK; Chui YL
Leuk Lymphoma; 2019 Dec; 60(12):3011-3019. PubMed ID: 31111759
[TBL] [Abstract][Full Text] [Related]
82. Leukemia cells impair normal hematopoiesis and induce functionally loss of hematopoietic stem cells through immune cells and inflammation.
Cui P; Zhang Y; Cui M; Li Z; Ma G; Wang R; Wang N; Huang S; Gao J
Leuk Res; 2018 Feb; 65():49-54. PubMed ID: 29306107
[TBL] [Abstract][Full Text] [Related]
83. Prenatal and postnatal myeloid cells demonstrate stepwise progression in the pathogenesis of MLL fusion gene leukemia.
Johnson JJ; Chen W; Hudson W; Yao Q; Taylor M; Rabbitts TH; Kersey JH
Blood; 2003 Apr; 101(8):3229-35. PubMed ID: 12515728
[TBL] [Abstract][Full Text] [Related]
84. Brief Report: Human Acute Myeloid Leukemia Reprogramming to Pluripotency Is a Rare Event and Selects for Patient Hematopoietic Cells Devoid of Leukemic Mutations.
Lee JH; Salci KR; Reid JC; Orlando L; Tanasijevic B; Shapovalova Z; Bhatia M
Stem Cells; 2017 Sep; 35(9):2095-2102. PubMed ID: 28758276
[TBL] [Abstract][Full Text] [Related]
85. ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia.
Wang Y; Skibbe JR; Hu C; Dong L; Ferchen K; Su R; Li C; Huang H; Weng H; Huang H; Qin X; Jin J; Chen J; Jiang X
Sci Rep; 2017 May; 7(1):1853. PubMed ID: 28500307
[TBL] [Abstract][Full Text] [Related]
86. MLL-AF9 initiates transformation from fast-proliferating myeloid progenitors.
Chen X; Burkhardt DB; Hartman AA; Hu X; Eastman AE; Sun C; Wang X; Zhong M; Krishnaswamy S; Guo S
Nat Commun; 2019 Dec; 10(1):5767. PubMed ID: 31852898
[TBL] [Abstract][Full Text] [Related]
87. RNAi-mediated silencing of MLL-AF9 reveals leukemia-associated downstream targets and processes.
Fleischmann KK; Pagel P; Schmid I; Roscher AA
Mol Cancer; 2014 Feb; 13():27. PubMed ID: 24517546
[TBL] [Abstract][Full Text] [Related]
88. Loss of MBD2 attenuates MLL-AF9-driven leukemogenesis by suppressing the leukemic cell cycle via CDKN1C.
Zhou K; Zhou M; Cheng L; Chen X; Wang X; Chu Y; Yu Q; Zhang S; Wang N; Zhao L; Wang D; Huang L; Wang C; Yuan W; Zhou J
Oncogenesis; 2021 Nov; 10(11):79. PubMed ID: 34789717
[TBL] [Abstract][Full Text] [Related]
89. Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia.
Röhrs S; Dirks WG; Meyer C; Marschalek R; Scherr M; Slany R; Wallace A; Drexler HG; Quentmeier H
Mol Cancer; 2009 Oct; 8():86. PubMed ID: 19835597
[TBL] [Abstract][Full Text] [Related]
90. [Prognostic significance of detecting MLL-AF9 fusion gene expression in patients with acute myeloid leukemia by real-time fluorescence quantitative PCR].
Huang S; Yang H; Gao L; Dou LP; Xu YY; Wang N; Wang LL; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1435-40. PubMed ID: 24370025
[TBL] [Abstract][Full Text] [Related]
91. Modeling human MLL-AF9 translocated acute myeloid leukemia from single donors reveals RET as a potential therapeutic target.
Barabé F; Gil L; Celton M; Bergeron A; Lamontagne V; Roques É; Lagacé K; Forest A; Johnson R; Pécheux L; Simard J; Pelloux J; Bellemare-Pelletier A; Gagnon E; Hébert J; Cellot S; Wilhelm BT
Leukemia; 2017 May; 31(5):1166-1176. PubMed ID: 27780967
[TBL] [Abstract][Full Text] [Related]
92. Hes1 suppresses acute myeloid leukemia development through FLT3 repression.
Kato T; Sakata-Yanagimoto M; Nishikii H; Ueno M; Miyake Y; Yokoyama Y; Asabe Y; Kamada Y; Muto H; Obara N; Suzukawa K; Hasegawa Y; Kitabayashi I; Uchida K; Hirao A; Yagita H; Kageyama R; Chiba S
Leukemia; 2015 Mar; 29(3):576-85. PubMed ID: 25234168
[TBL] [Abstract][Full Text] [Related]
93. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
Sandhöfer N; Metzeler KH; Rothenberg M; Herold T; Tiedt S; Groiß V; Carlet M; Walter G; Hinrichsen T; Wachter O; Grunert M; Schneider S; Subklewe M; Dufour A; Fröhling S; Klein HG; Hiddemann W; Jeremias I; Spiekermann K
Leukemia; 2015 Apr; 29(4):828-38. PubMed ID: 25322685
[TBL] [Abstract][Full Text] [Related]
94. Reprogramming of MLL-AF9 leukemia cells into pluripotent stem cells.
Liu Y; Cheng H; Gao S; Lu X; He F; Hu L; Hou D; Zou Z; Li Y; Zhang H; Xu J; Kang L; Wang Q; Yuan W; Gao S; Cheng T
Leukemia; 2014 May; 28(5):1071-80. PubMed ID: 24150221
[TBL] [Abstract][Full Text] [Related]
95. DNA hypermethylation-induced miR-182 silence targets BCL2 and HOXA9 to facilitate the self-renewal of leukemia stem cell, accelerate acute myeloid leukemia progression, and determine the sensitivity of BCL2 inhibitor venetoclax.
Ye S; Xiong F; He X; Yuan Y; Li D; Ye D; Shi L; Lin Z; Zhao M; Feng S; Zhou B; Weng H; Hong L; Ye H; Gao S
Theranostics; 2023; 13(1):77-94. PubMed ID: 36593968
[No Abstract] [Full Text] [Related]
96. A KLF4-DYRK2-mediated pathway regulating self-renewal in CML stem cells.
Park CS; Lewis AH; Chen TJ; Bridges CS; Shen Y; Suppipat K; Puppi M; Tomolonis JA; Pang PD; Mistretta TA; Ma L; Green MR; Rau R; Lacorazza HD
Blood; 2019 Nov; 134(22):1960-1972. PubMed ID: 31515251
[TBL] [Abstract][Full Text] [Related]
97. Iron overload promotes the progression of MLL-AF9 induced acute myeloid leukemia by upregulation of FOS.
Yang F; Cui X; Wang H; Zhang D; Luo S; Li Y; Dai Y; Yang D; Zhang X; Wang L; Zheng G; Zhang X
Cancer Lett; 2024 Feb; 583():216652. PubMed ID: 38242196
[TBL] [Abstract][Full Text] [Related]
98. Essential role of PR-domain protein MDS1-EVI1 in MLL-AF9 leukemia.
Zhang Y; Owens K; Hatem L; Glass CH; Karuppaiah K; Camargo F; Perkins AS
Blood; 2013 Oct; 122(16):2888-92. PubMed ID: 24021671
[TBL] [Abstract][Full Text] [Related]
99. The tumor suppressor MIR139 is silenced by POLR2M to promote AML oncogenesis.
Stavast CJ; van Zuijen I; Karkoulia E; Özçelik A; van Hoven-Beijen A; Leon LG; Voerman JSA; Janssen GMC; van Veelen PA; Burocziova M; Brouwer RWW; van IJcken WFJ; Maas A; Bindels EM; van der Velden VHJ; Schliehe C; Katsikis PD; Alberich-Jorda M; Erkeland SJ
Leukemia; 2022 Mar; 36(3):687-700. PubMed ID: 34741119
[TBL] [Abstract][Full Text] [Related]
100. Differential regulation of myeloid leukemias by the bone marrow microenvironment.
Krause DS; Fulzele K; Catic A; Sun CC; Dombkowski D; Hurley MP; Lezeau S; Attar E; Wu JY; Lin HY; Divieti-Pajevic P; Hasserjian RP; Schipani E; Van Etten RA; Scadden DT
Nat Med; 2013 Nov; 19(11):1513-7. PubMed ID: 24162813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
